

**Announcement  
 18 March 2013**
**Coloplast – transactions in connection with share buy-back programme**

As mentioned in Announcement No. 4/2013 Coloplast is initiating the second part of the share buy-back programme totalling up to DKK 1bn. The second part of the programme of DKK500m is expected to take place from 25 February, 2013 to 30 August, 2013 at the latest. The first part of the programme, of also DKK 500m, was executed in the 2011/12 fiscal year.

Under the second part of the programme the following transactions have been executed during the period 11 – 15 March 2013:

<b>Date</b>	<b>Number of shares</b>	<b>Average buying price</b>	<b>Amount DKK</b>
11.3.2013	13,000	313.68	4,077,777.60
12.3.2013	13,000	312.05	4,056,673.40
13.3.2013	13,000	314.20	4,084,654.60
14.3.2013	13,000	316.76	4,117,857.90
15.3.2013	13,000	318.36	4,138,696.90
<b>Accumulated until now under the programme</b>	200,487	305.69	61,285,909.70

Henceforth, Coloplast owns 8,654,429 own B shares of DKK 1 equal to 3.93% of the company's total share capital.

## For further information, please contact

### Investors and analysts

Lene Skole  
Executive Vice President, CFO  
Tel. +45 4911 1700

Ian S.E. Christensen  
Vice President, Investor Relations  
Tel. +45 4911 1800/+45 4911 1301  
Email: dkisec@coloplast.com

Henrik Nord  
Sr. Investor Relations Manager  
Tel. +45 4911 1800/+45 4911 3108  
Email: dkhno@coloplast.com

### Press and the media

Ulla Lundhus  
Head of Media and Positioning  
Tel. +45 4911 1929  
Email: dkul@coloplast.com

This announcement is available in a Danish and an English-language version.  
In the event of discrepancies, the Danish version shall prevail.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2013-3 All rights reserved. Coloplast A/S, 3050 Humlebæk, Denmark.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes Ostomy Care, Urology Care, Continence Care and Wound and Skin Care. We operate globally and employ around 8,000 people.